All In Biotech

Drug Trial Radar · NCT06151210

Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

Last checked: Nov 19, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 467 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

467

Actual

Start

Jan 31, 2024

Primary completion

Jul 10, 2025

Study completion Jul 15, 2025

Sponsor

Lead sponsor
Dong-A ST Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis

Conditions

  • Gastritis Acute
  • Gastritis Chronic

Interventions

  • DA-5219Drug

    1 tablet/day

  • Stillen® TabDrug

    3 tablets/day

  • DA-5219 PlaceboDrug

    1 tablet/day

  • Stillen® Tab PlaceboDrug

    3 tablets/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement rate of gastric mucosal erosionTime frame: Change from baseline at 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.